Related by context. Frequent words. (Click for all words.) 78 blind randomized 75 placebo controlled randomized 75 blind randomized placebo 71 Phase III randomized 71 randomized placebo controlled 69 prospective randomized controlled 69 multicenter randomized 68 multicentre 67 randomized controlled 66 placebo controlled clinical 66 prospective randomized 66 placebo controlled 65 multicenter 65 blinded placebo controlled 65 randomized clinical 64 prospective observational 64 randomized Phase III 64 randomized controlled clinical 63 blind placebo controlled 62 Randomized 61 randomized 61 nab paclitaxel 61 multicenter randomized double 60 dose escalation trial 60 active comparator 60 double blind placebo 60 multicenter clinical 60 randomized #:# 59 placebo controlled studies 58 subgroup analyzes 58 Phase 1b clinical 58 phase IIa 58 multicenter study 57 randomized controlled trial 57 Phase Ia 57 Phase 1a 57 retrospective cohort study 57 phase IIb 57 dose escalation study 57 randomized double 57 prospective cohort 57 dose regimens 56 label dose escalation 56 placebo controlled trials 56 Phase Ib 56 Phase 2b 56 substudy 56 TRITON TIMI 56 single ascending dose 56 Phase 1b trial 55 dose regimen 55 pharmacodynamics 55 relapsed refractory multiple myeloma 54 Phase 2b study 54 Phase IIa trial 54 phase 2a 54 dose cohorts 54 Phase 2a clinical 54 azacitidine 54 randomized controlled clinical trials 54 noninferiority 54 cohort 54 randomized clinical trials 53 safety tolerability pharmacokinetics 53 pivotal Phase III 53 multiple ascending dose 53 NRTI 53 Myocardial Infarction 53 nephrectomy 53 dose escalation 53 neoadjuvant 53 randomized controlled trials 53 axitinib 52 Phase IIa clinical 52 Phase 2b clinical 52 peginterferon alfa 2b 52 Phase 2b trial 52 Phase IIb trial 52 composite endpoint 52 Phase 1b 52 Phase III pivotal 52 #mg dose [003] 52 randomized trials 52 plus ribavirin 51 mg BID 51 mg kg dose 51 peginterferon alfa 2a 51 administered subcutaneously 51 confirmatory Phase III 51 SPIRIT III 51 RCTs 51 Phase III clinical 51 intravenously administered 51 dabigatran etexilate 51 adalimumab 51 Phase IIb clinical 51 RESOLUTE 51 RTOG 51 thymalfasin 51 tocilizumab 51 evaluable patients